Background: An estimated 5%-10% of all cutaneous melanoma cases occur in families. This review describes susceptibility genes currently known to be involved in melanoma predisposition, genetic testing of familial melanoma patients, and management implications.
Introduction
Cutaneous melanoma is one of the most aggressive human cancers, with an increasing incidence worldwide [1] . When detected at an early stage, high survival rates are reported 5 years after diagnosis [2] . Although new therapies are currently available for metastatic disease, survival for patients with advanced disease is still poor.
Melanoma pathogenesis is complex and heterogeneous, with environmental, phenotypic, and genetic factors contributing to its development. The main risk factors involved in the etiopathogenesis of cutaneous melanoma are a large number of common acquired melanocytic nevi, atypical melanocytic nevi, light skin phenotype, exposure to ultraviolet (UV) radiation, and a family history of melanoma [3] [4] [5] .
An estimated 5%-10% of all cutaneous melanoma cases occur in families. Familial melanoma is defined as a family in which either 2 first-degree relatives or 3 or more melanoma patients on the same side of the family (irrespective of degree of relationship) are diagnosed with melanoma [5] . In these families the pattern of heritability is consistent with an autosomal dominant inheritance with incomplete penetrance.
Germline susceptibility has been associated with mutations in high-penetrance melanoma predisposition genes, CDKN2A
(cyclin-dependent kinase 2A) and less frequently in CDK4 (cyclin-dependent kinase 4), BAP1 (breast cancer associated protein-1), TERT (telomerase reverse transcriptase), and POT1 (protection of telomeres 1), or with variants in intermediate-risk genes, MC1R (melanocortin 1 receptor) and MITF (microphthalmia-associated transcription factor) [6] [7] [8] [9] .
Currently, genetic testing is recommended in high-risk melanoma patients and families to improve early detection and reduce mortality. Individuals from high-risk melanoma families must receive genetic counseling so that they receive full information about the inclusion criteria for genetic test- and has been proposed as a hereditary cancer syndrome [39] [40] [41] [42] [43] [44] [45] resulting in a reduced receptor function with a switch from eumelanin to pheomelanin synthesis are classified as red hair color (RHC) or "R" variants and have been strongly associated with fair skin, freckling, UV radiation sensitivity, and inability to tan [24, 57] .
MC1R variants, mainly R alleles, have been associated
with an increased risk of melanoma independently of phenotypic features [56] . Notably, a stronger risk has been reported for patients with darkly pigmented skin [23] . It is indeed recognized that MC1R influences melanoma risk not only through its effect on pigmentation and UV sensitivity but also through additional biological pathways, including induction of antioxidant defenses, DNA repair mechanisms, and melanocyte proliferation, regulation, and differentiation [58] . In addition, inheritance of MC1R variants with CDKN2A mutations has been shown to increase penetrance of melanoma in families carrying CDKN2A mutations [23, 24] . Finally, carrying R variants has been associated with specific clinicodermoscopic features of melanoma such as hypopigmentation, structureless areas, atypia, and vessels [59] [60] [61] .
The MITF gene is a master regulator of melanocyte homeostasis encoding a lineage-specific transcription factor, involved in cell survival, differentiation, and proliferation [62] . A rare functional variant p.E318K in the MITF gene has been implicated in familial melanoma and in melanoma/renal cell carcinoma susceptibility [25, 26] . The p.E318K mutation alters MITF sumoylation, increasing the MITF transcriptional activity with upregulation of downstream genes. Clinically, a high nevus count, development of MPM, onset of melanoma before the age of 40, and nonblue eye color are phenotypic characteristics that have been associated with the p.E318K mutation [25, 63, 64] .
the CDK4 oncogene, the second identified high-risk melanoma susceptibility gene, encoding one of the binding partners of p16.
The CDK4 oncogene plays an important role at the G1/S phase cell cycle checkpoint (1B). When CDK4 is mutated, p16
cannot inhibit the CDK4 kinase activity resulting in increased phosphorylation of RB bound to E2F transcription factors with higher E2F release. E2F activates the transcription of pro-S phase cell cycle genes, promoting G1/S phase transition.
All CDK4 pathogenetic mutations cluster in codon 24
of exon 2, a critical site for p16 binding [16, 47] . The phenotype of CDK4-mutated families is indistinguishable from the CDKN2A phenotype, with early-onset cutaneous melanoma, development of MPMs, and presence of atypical nevi [48] .
In families negative for mutations in known high-risk genes, the introduction of next-generation sequencing meth- Telomere maintenance has been recently discovered as a key pathway in melanoma predisposition ( Figure 1C ).
The TERT gene encodes the catalytic subunit of telomerase, which is the ribonucleoprotein complex that maintains telomere length. TERT mutations induce increased expression of telomerase, thus promoting telomere stabilization and acting on cell aging, turnover, and senescence. A novel mutation occurring in the promoter region of the TERT gene, encoding the catalytic subunit of telomerase, has been recently identified in 2 melanoma families [18, 19] .
POT1 is a crucial member of the shelterin complex proteins, important for telomere maintenance. Mutations in the POT1 gene have been recently identified in a total of 12 CDKN2A-negative melanoma families [20, 21] . Additional shelterin complex genes, such as ACD and TERF2IP, were later found to be mutated in familial melanoma patients [54] .
Overall, germline mutations in POT1, ACD, and TERF2IP 
Management of Familial Melanoma Patients
Carriers of a CDKN2A mutation are at high risk of developing multiple melanomas and, in some families, pancreatic cancer [12, 13] . The identification of a deleterious CDKN2A mutation suggests that carriers should be included in intensive skin surveillance programs with skin examination, also including scalp, oral and genital mucosa, performed every 6 months. However, the frequency of dermatological visit (3-month, 6-month, or 1-year intervals) should be planned on the basis of the patient's risk factors; digital dermoscopy and clinical photography would be helpful for monitoring these patients. With regard to pancreatic cancer, patients should be aware of the current lack of effective screening guidelines [46, 66] . Overall, CDKN2A carriers are candidates for annual
Genetic Counseling and Testing
Genetic counseling should be offered to melanoma patients with hereditary predisposition so that they may better understand the meaning of the disease, pattern of inheritance, option of genetic testing, possible results and implications for other family members, and recommendations for primary and secondary prevention of melanoma and for psychological assessment [34, 65] .
To date, CDKN2A and CDK4 are the only genes recommended to be tested as single genes for genetic screening of melanoma predisposition [8, 31, 45] . Genetic testing of the Leachman et al [31] proposed a useful rule to select appropriate candidates eligible for genetic testing in melanoma with regard to the specific population or geographic area (Table   2 ): the rule of 2 for countries with a low incidence of melanoma (Southern Europe) and the rule of 3 for countries with a moderate-high incidence of melanoma (United States and Northern Europe). A rule of 4 for countries with a very high incidence of melanoma (Australia) has been suggested [65] .
To reduce the risk of uninformative negative results, it is important to identify the best candidate in the family for genetic testing, usually an individual with a personal presentation most suggestive of a CDKN2A mutation, such as young-onset or MPM patients [34] . If a CDKN2A mutation is detected in a family, screening of other family members is recommended. If no CDKN2A mutation is identified within a melanoma family, it should be stressed that the family is still at increased risk of melanoma on the basis of the family history. Patients should be aware of the difficulty of interpret- Geographic area/population with low melanoma incidence
Geographic area/population with moderate-high melanoma incidence The recommendation of avoiding smoking in cancer prevention programs has been recently suggested for CDKN2A mutation carriers after the description of an increased prevalence of tobacco-associated cancers in CDKN2A-mutated families [67] .
First-degree relatives (parents, siblings, children) will have a 50% chance of harboring the same mutation and risk. It is also prudent for children from familial melanoma kindreds to undergo routine skin examinations beginning at puberty.
Increased skin cancer screening, patients' skin self-examination education, and surveillance by physicians should be encouraged in all patients and relatives, irrespective of mutation status, for early detection of melanoma.
